- ►psu.edu [PDF] M Guerre-Millo, C Rouault, P Poulain, J André … - Diabetes, 2001 - Am Diabetes Assoc Peroxisome proliferator–activated receptor (PPAR)-α controls the expression
of genes involved in lipid metabolism. PPAR-α furthermore participates to
maintain blood glucose during acute metabolic stress, as shown in ... Cited by 135 - Related articles - BL Direct - All 6 versions
- ►nih.gov K Tordjman, C Bernal-Mizrachi, L Zemany, S … - Journal of Clinical Investigation, 2001 - Am Soc Clin Investig PPARα is a ligand-dependent transcription factor expressed at high levels in
the liver. Its activation by the drug gemfibrozil reduces clinical events in
humans with established atherosclerosis, but the underlying mechanisms are ... Cited by 184 - Related articles - BL Direct - All 12 versions
- ►endojournals.org M Haluzik, O Gavrilova, D LeRoith - Endocrinology, 2004 - Endocrine Soc Chronic peroxisome proliferator-activated receptor (PPAR)- activation improves
glucose metabolism in rodent models of insulin resistance and diabetes; however,
PPAR- deficiency was also reported to protect against high-fat diet (HFD)- ... Cited by 24 - Related articles - BL Direct - All 4 versions
CJ Chou, M Haluzik, C Gregory, KR Dietz, C … - Journal of Biological Chemistry, 2002 - ASBMB WY14,643 is a specific peroxisome proliferator-activated receptor α (PPARα)
agonist with strong hypolipidemic effects. Here we have examined the effect of
WY14,643 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes. ... Cited by 103 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org H Kim, M Haluzik, Z Asghar, D Yau, JW … - Diabetes, 2003 - Am Diabetes Assoc Abnormalities in insulin action are the characteristics of type 2 diabetes.
Dominant-negative muscle-specific IGF-I receptor (MKR) mice exhibit elevated
lipid levels at an early age and eventually develop type 2 diabetes. To ... Cited by 110 - Related articles - BL Direct - All 4 versions
- ►daegu.ac.kr [PDF] BN Finck, C Bernal-Mizrachi, DH Han, T … - Cell Metabolism, 2005 - Elsevier The role of the peroxisome proliferator-activated receptor-α (PPARα) in the
development of insulin-resistant diabetes was evaluated using gain- and
loss-of-function approaches. Transgenic mice overexpressing PPARα in ... Cited by 79 - Related articles - All 11 versions
C Bernal-Mizrachi, S Weng, C Feng, BN … - Nature medicine, 2003 - mechamlab.wustl.edu Glucocorticoids are among the most commonly prescribed medica- tions. Their
anti-inflammatory properties are crucial for people with organ transplants,
asthma, malignancies, rheumatologic syndromes, vision-threatening eye ... Cited by 103 - Related articles - BL Direct - All 10 versions
- ►nih.gov S Kersten, J Seydoux, JM Peters, FJ … - Journal of Clinical Investigation, 1999 - Am Soc Clin Investig Prolonged deprivation of food induces dramatic changes in mammalian metabolism,
including the release of large amounts of fatty acids from the adipose tissue,
followed by their oxidation in the liver. The nuclear receptor known as ... Cited by 692 - Related articles - BL Direct - All 11 versions
EH Koh, MS Kim, JY Park, HS Kim, JY Youn, … - Diabetes, 2003 - Am Diabetes Assoc Lipid accumulation in nonadipose tissues is closely related to the development
of type 2 diabetes in obese subjects. We examined the potential preventive
effect of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ... Cited by 103 - Related articles - BL Direct - All 6 versions
M Guerre-Millo, P Gervois, E Raspe, L Madsen … - Journal of Biological Chemistry, 2000 - ASBMB Fibrates and glitazones are two classes of drugs currently used in the treatment
of dyslipidemia and insulin resistance (IR), respectively. Whereas glitazones
are insulin sensitizers acting via activation of the peroxisome ... Cited by 382 - Related articles - BL Direct - All 5 versions
